Taylor Allan W, Nesheim Steven R, Zhang Xinjian, Song Ruiguang, FitzHarris Lauren F, Lampe Margaret A, Weidle Paul J, Sweeney Patricia
Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia2now with the Center for Global Health, Office of the Director, Centers for Disease Control and Prevention, Atlanta, Georgia.
Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.
JAMA Pediatr. 2017 May 1;171(5):435-442. doi: 10.1001/jamapediatrics.2016.5053.
Perinatal transmission of human immunodeficiency virus (HIV) can be reduced through services including antiretroviral treatment and prophylaxis. Data on the national incidence of perinatal HIV transmission and missed prevention opportunities are needed to monitor progress toward elimination of mother-to-child HIV transmission.
To estimate the number of perinatal HIV cases among infants born in the United States.
DESIGN, SETTING, AND PARTICIPANTS: Data were obtained from the National HIV Surveillance System on infants with HIV born in the United States (including the District of Columbia) and their mothers between 2002 and 2013 (reported through December 31, 2015). Estimates were adjusted for delay in diagnosis and reporting by weighting each reported case based on a model incorporating time from birth to diagnosis and report. Analysis was performed from April 1 to August 15, 2016.
Maternal HIV infection and antiretroviral medication, including maternal receipt prenatally or during labor/delivery and infant receipt postnatally.
Diagnosis of perinatally acquired HIV infection in infants born in the United States. Infant and maternal characteristics, including receipt of perinatal HIV testing, treatment, and prophylaxis.
The estimated annual number of perinatally infected infants born in the United States decreased from 216 (95% CI, 206-230) in 2002 to 69 (95% CI, 60-83) in 2013. Among perinatally HIV-infected children born in 2002-2013, 836 (63.0%) of the mothers identified as black or African American and 243 (18.3%) as Hispanic or Latino. A total of 236 (37.5%) of the mothers had HIV infection diagnosed before pregnancy in 2002-2005 compared with 120 (51.5%) in 2010-2013; the proportion of mother-infant pairs receiving all 3 recommended arms of antiretroviral prophylaxis or treatment (prenatal, intrapartum, and postnatal) was 22.4% in 2002-2005 and 31.8% in 2010-2013, with approximately 179 (28.4%) (2002-2005) and 94 (40.3%) (2010-2013) receiving antiretroviral prophylaxis or treatment during pregnancy. Five Southern states (Florida, Texas, Georgia, Louisiana, and Maryland) accounted for 687 (38.0%) of infants born with HIV infection in the United States during the overall period. According to national data for live births, the incidence of perinatal HIV infection among infants born in the United States in 2013 was 1.75 per 100 000 live births.
Despite reduced perinatal HIV infection in the United States, missed opportunities for prevention were common among infected infants and their mothers in recent years. As of 2013, the incidence of perinatal HIV infection remained 1.75 times the proposed Centers for Disease Control and Prevention elimination of mother-to-child HIV transmission goal of 1 per 100 000 live births.
通过抗逆转录病毒治疗和预防等服务可减少人类免疫缺陷病毒(HIV)的围产期传播。需要有关围产期HIV传播的全国发病率及预防机会错失情况的数据,以监测在消除母婴HIV传播方面取得的进展。
估算在美国出生的婴儿中围产期HIV病例数。
设计、背景和参与者:数据取自国家HIV监测系统,涉及2002年至2013年期间在美国(包括哥伦比亚特区)出生的HIV感染婴儿及其母亲(截至2015年12月31日报告的数据)。通过基于一个纳入从出生到诊断及报告时间的模型对每个报告病例进行加权,对诊断和报告延迟进行了调整。分析于2016年4月1日至8月15日进行。
孕产妇HIV感染及抗逆转录病毒药物,包括母亲产前或分娩时/分娩期间接受的药物以及婴儿出生后接受的药物。
对在美国出生的婴儿围产期获得性HIV感染进行诊断。婴儿和母亲的特征,包括围产期HIV检测、治疗和预防的接受情况。
美国围产期感染婴儿的估计年度数量从2002年的216例(95%CI,206 - 230)降至2013年的69例(95%CI,60 - 83)。在2002 - 2013年出生的围产期HIV感染儿童中,63.0%的母亲为黑人或非裔美国人,18.3%为西班牙裔或拉丁裔。在2002 - 2005年,共有236名(37.5%)母亲在怀孕前被诊断出感染HIV,而在2010 - 2013年这一比例为120名(51.5%);母婴对接受抗逆转录病毒预防或治疗所有3个推荐环节(产前、产时和产后)的比例在2002 - 2005年为22.4%,在2010 - 2013年为31.8%,在2002 - 2005年约179名(28.4%)以及在2010 - 2013年94名(40.3%)母亲在孕期接受了抗逆转录病毒预防或治疗。在整个期间,南部5个州(佛罗里达州、得克萨斯州、佐治亚州、路易斯安那州和马里兰州)占美国出生时感染HIV婴儿的687例(38.0%)。根据全国活产数据,2013年在美国出生的婴儿中围产期HIV感染发病率为每10万活产1.75例。
尽管美国围产期HIV感染有所减少,但近年来在感染婴儿及其母亲中预防机会错失情况普遍存在。截至2013年,围产期HIV感染发病率仍比疾病控制和预防中心提出的消除母婴HIV传播目标(每10万活产1例)高出1.75倍。